SEC Form 4 filed by CEO, CFO Finley John David

$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PALI alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Finley John David

(Last) (First) (Middle)
7750 EL CAMINO REAL, SUITE 2A

(Street)
CARLSBAD CA 92009

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, CFO
3. Date of Earliest Transaction (Month/Day/Year)
02/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.13 02/11/2025 A 47,000 (1) 02/11/2035 Common Stock 47,000 $0.00 47,000 D
Restricted Stock Units (2) 02/11/2025 A 40,000 (3) (3) Common Stock 40,000 $0.00 40,000 D
Explanation of Responses:
1. The shares subject to this option shall vest and become exercisable in twelve equal quarterly installments over a three-year period beginning on May 11, 2025, subject to the Reporting Person's continuous service through each such vesting date.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service through each such vesting date.
/s/ JD Finley 02/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PALI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PALI

DatePrice TargetRatingAnalyst
2/2/2022$5.00Buy
Ladenburg Thalmann
8/31/2021$7.00Buy
Maxim Group
More analyst ratings

$PALI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

    Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs seen to date On track to report topline data in first half of 2025 Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an upda

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

    PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California. Participation details are as foll

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Participates in Virtual Investor "What This Means" Segment

    Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor "What This Means" segment. As part of this segment, Dr. Heyer discussed the Company's positive preclinical data for its lead product candidate, PALI-2108, w

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PALI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PALI
SEC Filings

See more

$PALI
Leadership Updates

Live Leadership Updates

See more
  • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

    Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Palisade Bio Appoints Margery Fischbein to its Board of Directors

    Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

    Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Financials

Live finance-specific insights

See more
  • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PALI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more